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Abstract
Tauopathy in the brain of patients with Alzheimer’s disease starts in the entorhinal cortex (EC) and spreads anatomically in a
defined pattern. To test whether pathology initiating in the EC spreads through the brain along synaptically connected
circuits, we have generated a transgenic mouse model that differentially expresses pathological human tau in the EC and
we have examined the distribution of tau pathology at different timepoints. In relatively young mice (10–11 months old),
human tau was present in some cell bodies, but it was mostly observed in axons within the superficial layers of the medial
and lateral EC, and at the terminal zones of the perforant pathway. In old mice (.22 months old), intense human tau
immunoreactivity was readily detected not only in neurons in the superficial layers of the EC, but also in the subiculum, a
substantial number of hippocampal pyramidal neurons especially in CA1, and in dentate gyrus granule cells. Scattered
immunoreactive neurons were also seen in the deeper layers of the EC and in perirhinal and secondary somatosensory
cortex. Immunoreactivity with the conformation-specific tau antibody MC1 correlated with the accumulation of argyrophilic
material seen in old, but not young mice. In old mice, axonal human tau immunoreactivity, especially at the endzones of the
perforant pathway, was greatly reduced. Relocalization of tau from axons to somatodendritic compartments and
propagation of tauopathy to regions outside of the EC correlated with mature tangle formation in neurons in the EC as
revealed by thioflavin-S staining. Our data demonstrate propagation of pathology from the EC and support a trans-synaptic
mechanism of spread along anatomically connected networks, between connected and vulnerable neurons. In general, the
mouse recapitulates the tauopathy that defines the early stages of AD and provides a model for testing mechanisms and
functional outcomes associated with disease progression.
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Introduction
AD is characterized neuropathologically by the presence of
amyloid-b containing plaques and neurofibrillary tangles (NFTs)
composed of aggregated, fibrillar, hyperphosphorylated forms of the
microtubule-associated protein tau. The earliest stages of the disease
show accumulation of abnormal tau in the entorhinal cortex (EC)
whereas later stages show accumulation in the hippocampus followed
by neocortical areas [1]. As shown in Fig. 1, the EC is
monosynaptically connected to other hippocampal subregions and
it is trans-synaptically connected with affected regions in the
temporal and parietal lobes [2,3]. One of the most intriguing and
poorly explored questions in the field is whether pathology, and/or
dysfunction of the EC initiates anatomical progression of the disease,
or whether pathology and/or dysfunction in extrahippocampal areas
develops independently, and is unrelated to events occurring in the
EC. There are a number of interesting, albeit circumstantial
observations that support the trans-synaptic spread hypothesis for
AD both in terms of pathology development and functional outcome.
First, by simply charting the anatomical distribution of the pathology
in human post-mortem tissue, the affected areas appear to be trans-
synaptically linked [4]. Second, functional imaging studies in non-
human primates have shown that lesioning the rhinal cortex
(perirhinal and entorhinal) causes secondary dysfunction in the
temporal and parietal lobes [5]. Currently available AD transgenic
mouse models do not allow for studies of disease circuitry and
progression as they generally overexpress APP or tau in inappropri-
ate areas, or at high levels throughout the brain making it hard to
identify temporal and spatial progression between vulnerable areas.
To address this shortcoming, we have generated a transgenic mouse
model with restricted expression of pathological human tau that
predominates in the entorhinal cortex.We have performed a detailed
histopathological analysis of the mice to map the change in
distribution of tauopathy as the mice age. Our data support a
temporal and spatially defined mechanism of trans-synaptic spread
along anatomically connected networks, between connected and
vulnerable neurons that replicates the early stages of AD.
Results and Discussion
Histopathology studies demonstrate progressive
tauopathy radiating from the EC
A detailed histopathological analysis was performed on
relatively young (10–11 mon) and aged (,22 mon) neuropsin-
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tTA-tau (NT) transgenic mice using three different antibodies,
MC1, CP27 and AT8. The MC1 monoclonal antibody detects
human tau in an abnormal conformation [6] that is associated
with early stage NFT–tau in human AD patients [7]. In young NT
mice (Figs. 2A, D, G), abnormal human tau recognized by MC1
was most abundant in the medial EC (MEC). Relatively dense
staining was also seen in the lateral EC (LEC) and the para-(PaS)
subiculum while the presubiculum (PrS) was less intensely stained.
Dense staining was seen in superficial layers II and III of the EC,
whereas deeper layers showed considerably less staining. Human
tau was present in some cell bodies, but mostly in neurites within
the superficial layers of the MEC and LEC (Fig. 2G). Dense tau
staining was seen in the middle third of the molecular layer of the
DG and CA3 (Fig. 2D) but not the outer layer indicating tau in
axon terminals of the perforant pathway (pp) that originate from
layer II of the MEC [8]. In the CA1 and subiculum, the outer
molecular layer was labeled extensively (Fig. 2D), indicating tau in
perforant path terminals from layer III cells in both LEC and
MEC [8]. Mice expressing only the uninduced tau transgene
(control) showed negligible (Fig. 2C), or very limited immunore-
activity with the antibodies used, and it was usually restricted to
the mossy fibers (for example, antibody CP27, Fig. 3C). Some non-
specific staining in the fornix was seen in all mice, with all
antibodies. By 22 months of age, the distribution of human tau in
old NT mice had changed dramatically to resemble that seen in
more affected AD brain tissue (Braak stages II–III). Intense MC1
immunoreactivity was readily detected not only in neurons in the
superficial layers of the EC and throughout the subiculum (Figs. 2B,
E, H), but in pyramidal neurons in the hippocampus, especially in
CA1, and also in dentate gyrus granule cells (DG GCs) (Fig. 2E).
Somatodendritic staining with MC1 was intense for cells in the
MEC (Fig. 2F). Scattered MC1 positive neuronal cell bodies could
also be seen in the perirhinal and the parietal cortices (Fig. 2I), and
more extensively in the deeper layers of the EC.
The pattern of staining was reproduced in young and old NT
mice using a human specific tau antibody (CP27) that recognizes
all human tau, regardless of phosphorylation or conformation
status (Fig. 3). Subtle differences in the relative intensity of staining
in different areas were observed for different antibodies, especially
in the DG GC layer where CP27 staining was more intense and
extensive than MC1 (Figs. 3G and 4B vs. Fig. 2E). This could
either indicate differential sensitivity of the antibodies, differential
synthesis or clearance of tau forms recognized by the two
antibodies, or retarded development of the conformational change
in tau recognized by MC1.
To assess whether tauopathy could spread across a synapse, we
examined cells in the DG that are monosynaptically connected
with cells in the EC (Fig. 4). Young NT mice (Fig. 4A) showed
robust accumulation of CP27 immunoreactive human tau in the
endzones of the perforant pathway that originate from neurons in
the MEC and terminate in the middle third of the molecular layer
of the DG (area 3). Low, but detectable levels of immunoreactivity
were seen in the outer third of the molecular layer (area 4) which
represents terminals from neurons originating in the LEC. Some
human tau was seen in cells in the hilus (area 1), most likely in
mossy cells. Notably, human tau did not accumulate in DG GCs
(area 2) in young NT mice. Old NT mice however showed a very
different distribution of human tau (Fig. 4B). Robust accumulation
of human tau was now seen in DG GCs (area 2) and increased
accumulation of human tau was seen in layers 1, 2 and 4. The
appearance of tau in DGGCs strongly supports the idea that
tauopathy initiated in the EC can spread between cells that are
connected, but physically separated by a synapse. Interestingly, the
perforant pathway endzone in layer 3 was significantly depleted of
tau which coincided with accumulation in originating cell bodies
in the MEC (Fig. 2H, 2F). This apparent relocalization of tau from
axons to somatodendritic compartments is one of the earliest
events in the pathological cascade of early Alzheimer’s disease [1].
Tauopathy in AD is usually staged using the antibody AT8 [9].
This antibody recognizes phosphorylated epitopes S202/205 (in
both mouse and human tau) that are abundant in tau from AD
brain, but not normal brain [10]. In young NT mice, (Figs. 5A, D)
AT8 immunoreactive tau was mainly concentrated in the EC with
no staining visible in the hippocampal subfields. Cell body staining
was predominant with relatively less staining seen in neurites. In
old NT mice (Figs. 5B, E, F, G), there was considerably more
neurite staining throughout the EC (Fig. 5B, E), and in all fields of
the hippocampus (Fig. 5F), with cell body immunoreactivity being
seen in scattered neurons that were most prominent in pyramidal
cells in the CA1 and in DG GCs. As for MC1, in the old mice,
additional cell body staining was apparent in the deeper layers of
the EC, and in cells in the perirhinal and parietal cortices (Fig. 5G).
The control mouse (Fig. 5C) was essentially negative for this
antibody. Overall, the pattern of staining, including extensive
staining of cell bodies and neurites throughout the EC and
hippocampus was reminiscent of that described for early Braak
stages of AD [9].
Although the exact type of tau associated with functional
impairment and degeneration is not known [11], the accumulation
Figure 1. Monosynaptic and trans-synaptic cortico-hippocam-
pal and cortico-cortico connections. Solid lines indicate projections
radiating out from the EC, dotted lines indicate projections to the EC.
Monosynaptically connected regions are connected across one synapse.
Trans-synaptic regions are separated by more than one synapse.
doi:10.1371/journal.pone.0031302.g001
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of insoluble, conformationally abnormal, hyperphosphorylated tau
into mature neurofibrillary tangles in the somatodendritic cell
compartment is generally associated with more severe pathology,
degeneration and cell death. To test whether mature tangles had
formed in the NT mice, we examined tissue sections stained with
thioflavin S (thioS), a dye that binds to proteins in a b- sheet
conformation, indicative of tau in mature tangles (Fig. 6). Special
care was taken to mask lipofuscin fluorescence which is significant
in old mice. A small number of neurons restricted to the MEC
were positive for thioS in old NT mice (Figs. 6B, E). Young NT
(Fig. 6D) and old control mice (Figs. 6A, C) were essentially
negative. Not all of the tau immunoreactive neurons in the MEC
of old NT mice were thioS positive, and cells in the LEC, CA1 and
DG GC layer were thioS negative, as were neurites and axonal
terminals in the perforant pathway. As cells with the highest level
of human tau occur in the MEC, the lack of staining in other areas
Figure 2. Progressive spread of tauopathy in NT mice identified by antibody MC1. Fig. 2A shows tau immunolabeled with the human tau
specific, conformational antibody MC1 in a young NT mouse at low power, and higher power (Figs. 2D, G). Fig. 2B shows MC1 immunolabeling in an
old NT mouse at low power, and higher power (Figs. 2E, H). Fig. 2F shows high power image of cells immunolabeled with MC1 within the MEC. Old
NT mice show extensive accumulation of human tau in cell bodies in the EC and subiculum (Fig. 2H), and in synaptically connected areas in the
hippocampus and neocortex (Fig. 2E). Fig. 2I shows accumulation of human tau in neurons of the perirhinal cortex and into the parietal region in the
old NT mouse. Note the lack of neurite staining in the perirhinal cortex compared to the LEC. Fig. 2C shows lack of immunolabeling with the human
specific antibody in an old, littermate control mouse (single transgenic tau responder mouse, no tTA) except for the non-specific staining of the fornix
that was seen with all antibodies. MEC=medial entorinal cortex, LEC= lateral entorhinal cortex, Pe = perirhinal cortex, Par = parietal cortex,
DG=dentate gyrus, CA1, CA3=CA fields of hippocampus, Su = subiculum, Prp-PaS= pre-parasubiculum, pp=perforant pathway endzone. Figs. 2A–C
magnification = 26, Figs. 2D, E magnification= 46, Figs. 2G–I magnification= 106. Fig. 2F magnification= 406.
doi:10.1371/journal.pone.0031302.g002
Spread of Tau Pathology In Vivo
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31302
is most likely explained by the lower tau levels rather than by
regional sensitivity to tangle formation, but the latter interpreta-
tion cannot be ruled out in these studies.
Altered conformation of proteins can also be visualized by silver
staining using one of several methods [12]. Argyophilic plaques,
tangles and neurites are abundant in the human AD brain.
Abundant, argyrophilic cell body and neurite staining was also
seen in the old (Figs. 7B, D, F), but not the young NT mice
(Fig. 7A), and it was related to tauopathy development rather than
aging as parallel-processed, old littermate control mice were
negative (Figs. 7C, E, G). The distribution of histopathology in the
old NT mouse was extensive, with robust staining being seen in
cells in the EC, as well as in the subiculum (Fig. 7D). Staining was
also extensive in the CA1, but to a lesser extent in the DG GC
layer (Fig. 7F). In general, the distribution of silver-staining
matched that seen with the MC1 antibody more closely than that
seen with the CP27 or AT8 antibodies, suggesting that it is the
conformational change in tau recognized by MC1 that is
recognized by the silver stain. Interestingly, MC1 immunoreac-
tivity was robust in neurites in the young NT mice but these mice
were negative for silver staining. Therefore the silver stain
recognizes a more advanced conformational abnormality that lies
Figure 3. Progressive spread of tauopathy in NT mice identified by antibody CP27. Fig. 3 shows mice immunolabeled with CP27 (total
human tau) at low power in a young NT mouse (Fig. 3A), an old NT mouse (Fig. 3B) or a control mouse (Fig. 3C). Higher power images from the young
NT mouse (Figs. 3D, F), old NT mouse (Figs. 3E, G) with antibody CP27. CP27 is one of several antibodies that show non-specific staining of mossy
fibers in the control mouse. Figs. 3D and E show the EC and subiculum whereas Figs. 3F and G show the CA and DG regions of the hippocampus.
Figs. 3A–C magnification= 26, Figs. 3D–G magnification= 106.
doi:10.1371/journal.pone.0031302.g003
Figure 4. Progressive spread of tauopathy to monosynaptically
connected regions of the hippocampus. Young NT mice (Fig. 4A)
show accumulation of human tau immunolabeled with CP27 predom-
inately in the endzones of the perforant pathway that terminate in the
middle third of the molecular layer of the DG (area 3). Terminals from
neurons in the LEC terminating in the outer third of the molecular layer
are shown in area 4. Human tau was also seen in cells in the hilus (area
1). Granule cell layers of the DG (area 2) did not accumulate human tau
at this age. Old NT mice (Fig. 4B) show accumulation of human tau in
cell bodies in the granule cells of the DG (area 2). Increased
accumulation of human tau is seen in layers 1, 2 and 4 but the
perforant pathway endzone in layer 3 was significantly depleted of tau.
Magnification= 206.
doi:10.1371/journal.pone.0031302.g004
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between pre-tangle MC1 immunoreactivity seen in the young
mice, and the overt conformational change recognized by thioS,
which in the old mice, is restricted to cells in the MEC.
Trans-synaptic spread of pathology identified, but
mechanism unknown
One of the most intriguing observations from our studies is the
appearance of tauopathy in cells outside of the entorhinal cortex.
As shown in Fig. 4B, granule cells in the DG of old NT mice
accumulate human tau protein, but it is unknown whether the
human tau protein accumulated in the DG GCs derives solely
from uptake or transfer of human tau from neurons in the EC, or
if the human tau protein could be generated from endogenously
produced human tau mRNA in the DG GCs resulting from
‘‘leaky’’ expression of the transgene. To test whether endogenously
produced human tau in the DG GCs could be contributing to the
Figure 5. Progressive spread of tauopathy in NT mice identified by antibody AT8. Fig. 5 shows mouse brain tissue immunolabeled with
AT8 (phospho-tau S202/205) at low power in a young NT mouse (Fig. 5A), an old NT mouse (Fig. 5B) or a control mouse (Fig. 5C). Higher power
images from the young NT mouse (Fig. 5D), or old NT mouse (Figs. 5E–G) with antibody AT8. Figs. 5D and E show the EC and subiculum whereas 5F
shows the CA and DG regions of the hippocampus. Fig. 5G shows the boundary between the LEC and the perirhinal cortex in the old NT mouse. Note
the scarcity of neurite staining in the perirhinal cortex compared to the LEC. Figs. 5A–C magnification= 46, Figs. 5D–G magnification= 106.
doi:10.1371/journal.pone.0031302.g005
Figure 6. Mature, filamentous neurofibrillary tangle formation in the EC of old NT mice. Fig. 6A shows lack of thioS staining of neurons in
the EC of an old control mouse. The boxed area is shown in the high power image in Fig. 6C. Fig. 6B shows thioS positive neurons in the EC of an old
NT mouse. The boxed area is shown in the high power image in Fig. 6E. Fig. 6D shows lack of thioS staining in the same region of the young NT
mouse. Figs. 6A and B magnification = 106, Figs. 6C–E magnification= 206.
doi:10.1371/journal.pone.0031302.g006
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tauopathy seen there, we collected approximately 1000 individual
neurons by laser-capture microdissection (LCM) from the DG GC
layer from old (Fig. 8A) and young (Fig. 8B) mice and assessed
whether human tau mRNA was expressed in them. For this
experiment, young mice at ,4 months of age were sampled to
reduce the likelihood that incipient pathology had developed. Old
NT, young NT and non transgenic mouse tissue sections were
double immunolabeled with both CP27 and NeuN to ensure that
neurons were isolated. Fig. 8C shows total RNA extracted from
LCM isolated cell populations from one mouse from each type. A
gel image from the 2100 Bioanalyzer, which employs capillary gel
electrophoretic methodology to measure RNA integrity (RIN) and
abundance, demonstrated the quality of sample from the LCM
isolated cells in young mice - Non Tg (RIN 6.3; 418 pg/ml; total
yield 4.18 ng), tau protein negative (Tau2) GCs (RIN 8.1;
443 pg/ml; total yield 4.43 ng), and old mice - tau protein positive
(Tau+) GCs (RIN 8.6; 907 pg/ml; total yield 9.07 ng) and Tau2
GCs (RIN 7.8; 351 pg/ml; total yield 3.51 ng). The level of human
tau mRNA was then measured by quantitative (q) RT-PCR. To
confirm the specificity of our human tau primers, LCM was used
to isolate DG GCs from a non Tg young mouse that had been
processed in the same way as the young NT mouse. QRT-PCR
identified no amplification from the non Tg sample (CT.40)
demonstrating that the primers were completely human specific
(Fig. 8D). To assess whether amplification could result from
residual DNA contamination even after DNAase treatment, RNA
from DG GCs was used for qPCR with, or without the reverse-
transcription step required to synthesize cDNA. Human tau
amplicons in the sample that had not been reverse-transcribed
were found to be at least twenty five fold (25X) lower than in the
transcribed samples, suggesting that genomic DNA transgene
priming resulted in only very low levels of PCR amplification
compared to mRNA priming. Fig. 8D shows human tau
expression in the human tau protein negative DG GCs (Tau2
GCs) from a young NT mouse (left side of panel), and in human
tau protein positive (Tau+ GCs) and negative (Tau2 GCs) DG
GCs from an old NT mice (right side of panel). Surprisingly, in the
young NT mouse where all of the DG GCs were tau protein
negative, the Tau2 GCs had low but detectable levels of human
tau mRNA after normalization to b-actin. In old mice, human tau
mRNA was again detected in DG GCs from the NT mouse, both
in cells that were positive or negative for tau protein. Relative
expression changes (22DDCT) between the two populations of DG
GCs in the old NT mouse showed a 27% increase in expression
levels between Tau2 and Tau+ DG GCs. A second, old NT
mouse also had quantifiable levels of human tau mRNA in all
three cell populations, with mRNA levels in Tau+ GCs.Tau2
GCs (data not shown). The reason for this apparent increase is
unknown but if it is significant in a larger sample group, it could
reflect a feedback mechanism whereby tau transcription is
upregulated if tau is losing its ability to perform its’ normal
function as it accumulates in the cytosol in the Tau+ DG GCs.
The apparent increase in tau levels in old compared to young
samples could reflect an age-dependent increase in transcription,
or it could simply represent inter-animal variability.
Despite the absence of detectable human tau protein immuno-
reactivity in the tau negative DG GCs from young or old NT
mice; human tau mRNA was identified in cells from three separate
experiments suggesting that transgene expression was slightly
leaky. To further examine whether ectopic expression in the DG
GCs could explain the accumulation of protein at old age, we
examined mice from two other crosses to the neuropsin tTA
activator mouse. The first cross was to a reporter gene expressing
LacZ with a nuclear localization signal to restrict the cellular
distribution of the reporter to the nucleus of the cell in which it was
produced [13]. As shown in Fig. 8E, positive staining for LacZ was
restricted to very few cells in the DG GC layer. The second cross
was to a mutant APP responder line. When crossed to the
neuropsin-tTA activator, this mouse expresses APP predominantly
in the EC as expected (data not shown), but due to secretion of Ab,
Figure 7. Silver staining in NT mice. Fig. 7A shows a lower power image of argyrophilic material in the hippocampus and cortex of a young NT
mouse (Fig. 7A), an old NT mouse (Fig. 7B) and a control mouse (age matched to the old NT mouse) (Fig. 7C). Higher power images from the EC and
subiculum of the old NT mouse (Fig. 7D) or control mouse (Fig. 7E). Figs. 7F and G show high power images of argyrophilic neurons in the
hippocampus of the old NT mouse (Fig. 7F) or control mouse (Fig. 7G). Note the relatively abundant, dense staining in EC, subiculum and CA regions
compared to the faint staining in the DG, which mirrors the staining pattern with MC1. Figs. A, B and C magnification= 46, Figs. 7D–G
magnification = 106.
doi:10.1371/journal.pone.0031302.g007
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plaques accumulate in regions outside of the EC, including layers of
the DG. Of note, the cells of the DG GC layer did not accumulate
APP/Ab supporting our observations that ectopic expression of
responder genes in this cell layer is negligible. Therefore, despite our
findings of some human tau mRNA in DG GCs, ectopic expression
in these cells is very limited and unlikely to account for the extensive
immunolabeling with human tau specific antibodies seen in the old
mice. As we pooled many DG GCs and analysis of mRNA levels by
qPCR is extremely sensitive, the actual number of cells contributing
the human tau mRNA could be a very low percentage of the total
that were human tau protein positive. How human tau protein
accumulating in DG GCs that were likely to be human tau mRNA
negative was derived is unknown, but it is possible that tau was
released from cells originating in the EC, and internalized by DG
GCs synapsing on to them. In support of this mechanism, a recent
study has shown that tau can be released from cells via exosomes
and tau positive exosomes have been identified in human CSF from
AD patients [14].
Figure 8. LCM-isolation of cell populations and assessment of mRNA levels by qRT-PCR. Fig. 8A shows high power images of frozen
sections from an old NT mouse double-immunolabeled with antibodies recognizing the neuronal marker NeuN (green) and human tau CP27 (red),
before LCM capture of dentate gyrus granule cells (GCs). Co-localization between CP27 and the neuronal marker NeuN indicates that expression of
human tau was neuronal in origin and glial expression was negligible, or absent. Human tau positive neurons (Tau+ GC, yellow cells, solid white
arrow) and tau negative neurons (Tau2 GC, green cells, open blue arrow) were isolated. Fig. 8B shows the GC layer from a young mouse. Granule cell
neurons in the DG were not immunoreactive for human tau at this age therefore only green neurons (Tau2 GCs) in this region were isolated by LCM.
Fig. 8C shows a gel image from the Agilent Bioanalyzer of RNA extracted from LCM isolated cells. Fig. 8D shows human tau expression in LCM isolated
non Tg and Tau2 GC of a young animal and in Tau+ GC and Tau2 GC neurons from an old NT mice. The relative expression changes (22DDCT)
between the cell types were calculated after normalization to b-actin expression. Error bars represent the SD for triplicates of each RT-cDNA sample
used for qPCR. One old and one young mouse are represented in Fig. 8D; analyses were performed on cells from three individual old mice, and two
young mice. Fig. 8E shows the DG of the neuropsin-tTA-lacZ reporter gene mouse (3 months of age) with GCs expressing the responder indicated
(arrows). Fig. 8F shows the DG of a neuropsin-tTA-APP mouse with the DG GCs indicated. Mice were 22 months of age; two mice were examined.
Despite the presence of extensive plaque pathology in adjacent layers, no APP/Ab staining was seen in the DG GCs from this mouse line. Figs. 8A, B
magnification = 206. pp =perforant pathway endzone, H= hilus, GC=dentate gyrus granule cells.
doi:10.1371/journal.pone.0031302.g008
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In general, our NT mouse model replicates the spatial and
temporal aspects of the earliest stages (I–III) of Braak staging of
tauopathy in Alzheimer’s disease. We have demonstrated that tau
pathology initiating in the EC can spread to other synaptically
connected brain areas as the mice age, supporting the idea that
AD progresses via an anatomical cascade as opposed to individual
events occurring in differentially vulnerable regions. Thus, our NT
transgenic mouse provides a model in which the spatial and
temporal propagation of the disease can be predicted, and
correlative functional outcomes can now be tested. Given that
the earliest Braak stages are not associated with cognitive decline,
identifying an EC based ‘‘biomarker’’ for pathology or dysfunction
and developing therapeutic strategies to prevent propagation are
likely to be both possible, and beneficial.
Materials and Methods
Ethics statement
Animals were used in full compliance with the National
Institutes of Health/Institutional Animal Care and Use Commit-
tee guidelines. The protocol was approved by the Committee on
the Ethics of Animal Experiments of Columbia University under
protocol # AC-AAAB7457.
Transgenic mice
To achieve differential expression in the entorhinal cortex we
have used an inducible mouse line (neuropsin-tTA; the ‘‘activa-
tor’’) in which the tTA activator is driven by the promoter for the
neuropsin gene [15]. This results in robust expression of tTA in
the EC, primarily in superficial layers of the MEC, and to a lesser
extent in the LEC and pre- and para-subiculum. Neuropsin-tTA-
Tau (NT) mice were generated by crossing the neuropsin-tTA
activator line with a tetracycline inducible, tau Tg mouse, line
rTg4510 (the ‘‘responder’’). This line consists of a tetracycline-
operon–responsive element (TRE) placed upstream of a cDNA
encoding human four-repeat tau with the P301L mutation (4R0N
tauP301L) [11]. Immunohistochemical analysis of neuropathology
has been performed on n=425 mice from each age group with
consistent results. Two other responder lines were crossed to the
neuropsin-tTA line to test for ectopic expression of the
transactivator protein in the DG. The second responder line
consists of the TRE placed upstream of a cDNA encoding a
nuclear localized fusion of lacZ and green fluorescent protein [13].
Data from mice at 3 months of age was supplied by Dr. Joanna
Jankowsky. The third responder line expresses mutant APP (line
B6.Cg-Tg (tetO-APPSwInd) 885 Dbo/J). This APP line was
obtained from Jackson laboratories and crossed to the neurop-
sin-tTA line. Data shown is from mice at 22 months of age. All
figures show one mouse from each group.
Immunohistochemistry
Mouse brains were harvested after transcardial perfusion and
drop-fixed in 4% paraformaldehyde overnight, followed by
cryoprotection treatment in 30% sucrose in PBS for 16 hours.
Free-floating brain sections (30 mm) from brains sectioned in the
horizontal plane were used for immunohistochemistry using
SuperPicTureTM polymer detection kit (Zymed, San Francisco,
CA). Sections were washed with PBS for 10 minutes, and then
treated with 3% H2O2 in PBS for 10 minutes. The sections were
then transferred to a microfuge tube that contained 1 ml of
primary antibody diluted in PBS containing 0.3% Triton and 5%
normal serum, and incubated at 4uC overnight on a rotator. After
three washes with PBS-T (0.1% Triton-X 100), the sections were
incubated for 10 minutes with HRP polymer conjugate. Following
three washes with PBS-T, immunoreactive material was visualized
using DAB as chromagen. The stained sections were mounted on
slides and inspected by light microscopy. Three monoclonal
antibodies were used for detection of tau. MC1 (gift of Dr. Peter
Davies) detects an abnormal conformational epitope of tau that is
associated with NFT formation [7]. CP27 is specific for human tau
(conformation and phosphorylation status independent, gift of Dr.
Peter Davies). AT8 recognizes tau phosphorylated at S202/205, in
mouse and human tau [10]. Staining for APP/Ab shown in Fig. 8F
was performed on horizontal sections from 22 month old
neuropsin-tTA-APP mice, as described for tau immunohistochem-
istry, using the 6E10 antibody (Covance Inc.) which recognizes
human APP/Ab.
LacZ staining
Mouse brains were harvested at 3 mo of age after transcardial
perfusion and drop-fixed in 4% paraformaldehyde for 2 hours,
followed by cryoprotection in 30% sucrose/1x PBS for 24 hours.
Horizontal sections (35 mm) were mounted and allowed to air dry
for 30 minutes prior to brief incubation in PBS+2 mM MgCl2.
Slides were then pretreated in 0.1 M NaPO4, 2 mM MgCl2, 0.2%
NP40, and 0.1% sodium deoxycholate, before being developed in
a 0.6% X-Gal (5 PrimeTM)/10 mM potassium ferri/ferrous
cyanide solution in the dark for 1 hr at 37 C [16]. Development
was stopped with 16 HEPES buffered saline, 0.1% Triton X,
1 mM EDTA, followed by a 1 hr post fixation with 4%
paraformaldehyde. Sections were counterstained with Nuclear
Fast Red, dehydrated through alcohol, and mounted in a xylene-
based medium.
Thioflavin-S staining
To reduce the lipofuscin fluorescence background staining in
aged mice, a modified thioflavin-S staining protocol [17] was used
as follows. Free floating brain sections were incubated in 0.3%
KMnO4 for 3–5 minutes, washed with water, then treated with a
solution of 1% K2 S2O5 and 1% oxalic acid until the brown color
was removed from the tissue (20–40 secs). Sections were then
stained with 0.05% thioflavin-S in 50% ethanol in the dark for
8 minutes, followed by differentiation in two changes of 80%
ethanol for 10 secs each and three washes in large volumes of
distilled water. The sections were mounted and coverslipped with
VectaShield mounting medium (Vector Lab), and observed with a
fluorescence microscope.
Bielschowsky silver staining
Brain sections (30 mm) prepared as for IHC were mounted on
slides and silver stained according to Bielschowsky’s method as
described [12].
Immuno Laser-Capture Microdissection (LCM)
Mouse brains were rapidly removed after cervical dislocation,
and were progressively frozen by slow immersion (,60 sec) in dry
ice chilled isopentane. The frozen brains were embedded in
O.C.T. and sectioned horizontally at 10 mm. The sections were
mounted on pre-treated membrane slides (according to manufac-
turer’s manual, Carl-Zeiss MicroImaging, LLC) and stored at
280uC before use. CP27 (1:25) antibody was used to label human
tau positive neurons and Alexa Fluor 568 was used as a secondary
antibody (1:25). For double-immunolabeling, sections were
incubated with CP27 as before, and with NeuN polyclonal
antibody (1:25, Millipore) with Alexa Fluor 488 used as secondary
antibody (1:25). Antibodies were diluted in PBS containing
200 U/ml of RNAse inhibitor. All staining procedures were
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performed on ice, using RNase-free conditions. The brain sections
were fixed in acetone for 3 minutes, followed by a PBS wash for
30 secs, then incubated with CP27 antibody for 10 minutes. After
rinsing the slides in PBS (10 dips), secondary antibody was applied
for 2 minutes. Slides were briefly rinsed with PBS and H2O, and
dehydrated through 70%, 95%, and 100% Ethanol (10 dips each).
The slides were kept at room temperature and used for LCM
within 90 minutes. Human tau positive neurons were identified
using fluorescence microscopy, laser captured with a PALM
MicroLaser Systems (Carl-Zeiss MicroImaging, LLC) and col-
lected using AdhesiveCaps. One thousand cells were captured
from each region and used for quantitative RT-PCR analysis.
Quantitative RT-PCR (qPCR)
RNA was extracted from each LCM cell population using the
ArcturusPicoPure RNA Kit (Applied Biosystems, Foster City, CA),
also with a DNase I treatment step. RNA extracted from LCM
isolated cells was analyzed using a 2100 Bioanalyzer (Agilent,
Technologies, Santa Clara, CA). 2.5 ng of RNA was employed for
first strand cDNA synthesis, in a 20 ml reaction volume using a 1:1
ratio of random hexamer and oligo-dT primers and SuperscriptH
III RT enzyme (Life Technologies Inc., Carlsbad, CA). cDNA
products were diluted with 70 ml RNAse free water, prior to
quantitative PCR of the human tau transgene and the house-
keeping gene b-actin. PCRs were performed by monitoring in real
time the increase in fluorescence of the SYBR Green dye, using a
Bio-Rad iQ5 detector system (Bio-Rad, Hercules, CA). Primers
specific to the human transgene (59-CCCAATCACTGCCTA-
TACCC-39 and 59-CCACGAGAATGCGAAGGA-39 as pub-
lished [11]), or b-actin (59-GCTCTTTTCCAGCCTTCCTT-39
and 59-AGTACTTGCGCTCAGGAGGA-39) were employed in
triplicate in 20 ml PCR reactions using 250 nM each primer pair,
8 ml of diluted cDNA and 10 ml of iQ SYBR Green Supermix,
using amplification conditions as follows: 95uC for 3 minutes,
followed by 40 cycles of denaturation at 95uC (10 secs), priming at
60uC (30 secs), and extension and fluorescence capture at 72uC
(30 secs). A melt curve was also employed to test the specificity of
each primer pair.
A standard curve was generated for each gene, using dilutions of
cDNA synthesized from a control RNA sample extracted from
mouse cortex: 100 ng cDNA, 1 ng cDNA and 0.1 ng of cDNA
input. Relative expression changes were calculated using the
22DDCT method, where the CT is defined as the fractional cycle
number in which the template amplification reaches a fixed
threshold [18]. Data were analyzed in GraphPad Prism v5.
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